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Abstract
Introduction Over the past decade, the potential for drug-
associated progressive multifocal leukoencephalopathy
(PML) has become an increasingly important consideration
in certain drug development programmes, particularly
those of immunomodulatory biologics. Whether the risk of
PML with an investigational agent is proven (e.g. extrap-
olated from relevant experience, such as a class effect) or
merely theoretical, the serious consequences of acquiring
PML require careful risk minimisation and assessment. No
single standard for such risk minimisation exists. Vedoli-
zumab is a recently developed monoclonal antibody to
a4b7 integrin. Its clinical development necessitated a
dedicated PML risk minimisation assessment as part of a
global preapproval regulatory requirement.
Objective The aim of this study was to describe the mul-
tiple risk minimisation elements that were incorporated in
vedolizumab clinical trials in inflammatory bowel disease
patients as part of the risk assessment and minimisation of
PML programme for vedolizumab.
Methods A case evaluation algorithm was developed for
sequential screening and diagnostic evaluation of subjects
who met criteria that indicated a clinical suspicion of PML.
An Independent Adjudication Committee provided an
independent, unbiased opinion regarding the likelihood of
PML.
Results Although no cases were detected, all suspected
PML events were thoroughly reviewed and successfully
adjudicated, making it unlikely that cases were missed.
Conclusion We suggest that this programme could serve as
a model for pragmatic screening for PML during the
clinical development of new drugs.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40264-018-0669-8) contains supple-
mentary material, which is available to authorized users.
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Key Points
PML risk minimisation is a consideration in many
drug development programmes involving
investigational or approved immunomodulatory
agents.
This programme for Risk Assessment and
Minimisation of PML (RAMP) demonstrated that
practical and effective screening and surveillance
measures can be applied successfully in clinical trials
to help minimise and assess the potential risk of
PML associated with new drugs.
No cases of PML were identified during the
development of vedolizumab following rigorous risk
minimisation and assessment via the RAMP.
The overall number of new unexplained neurological
events detected, and the number of costly or invasive
procedures (i.e. magnetic resonance imaging, lumbar
puncture) required by the stepwise evaluation were
low in an inflammatory bowel disease population.
1 Introduction
Progressive multifocal leukoencephalopathy (PML) is a
rare but serious demyelinating opportunistic infection of
the central nervous system caused by the JC polyomavirus.
This virus is near ubiquitous, with approximately 55–60%
of healthy adults harbouring a clinically latent infection.
However, PML rarely develops in immunocompetent hosts
[1–3]. The infection was originally recognised for its
association with severe immunocompromise, such as
occurs with haematologic malignancies, human immun-
odeficiency virus infection/acquired immune deficiency
syndrome and solid organ transplantation [4]. More
recently, PML has also been reported in association with a
number of immunosuppressive agents used to treat
immune-mediated diseases and cancer, [2, 5–10], particu-
larly monoclonal antibodies directed against cell surface
integrins [11–13]. In 2005, three cases of PML were
reported in clinical trials of natalizumab, among approxi-
mately 3000 patients, with a mean latency of 18 months
[14–16]. The findings were surprising in light of the safety
profile of natalizumab up to that point, and the absence of a
prior association between its mechanism of action (i.e.
antibody against a4 integrin) and PML. Efalizumab, a
monoclonal antibody against aLb2 integrin, was also
shown to have an association with PML, which ultimately
led to its withdrawal from the market [17]. Risk estimates
of integrin therapeutics appeared to be elevated, even when
compared with other classes of drugs associated with PML.
These facts raised the possibility that other integrin
antagonists that target the immune system might also be
associated with an increased risk, necessitating appropriate
PML risk minimisation and assessment measures in clini-
cal trials [18]. However, the rarity of PML, along with its
varied clinical presentation, render early diagnosis chal-
lenging. Currently, no validated tools exist to systemati-
cally screen for PML; therefore, systematic approaches
toward PML risk minimisation with early detection of
possible cases, both in clinical trials and other clinical
settings, are needed. In this study, we describe the Risk
Assessment and Minimisation of PML (RAMP) pro-
gramme, designed to address this need. The RAMP was
created for, and implemented during, the clinical devel-
opment of vedolizumab, a monoclonal antibody to a4b7
integrin for the treatment of inflammatory bowel disease
(IBD), ulcerative colitis (UC) and Crohn’s disease (CD).
In creating the RAMP to support vedolizumab devel-
opment, it was unclear if an approach toward proactive risk
minimisation could be validated in the absence of actual
PML events. The exclusive binding of vedolizumab to
integrin a4b7 inhibits the adhesion of certain types of B
and T lymphocytes to mucosal addressin cell adhesion
molecule (MAdCAM-1), which is primarily expressed on
gut vascular endothelial cells. This fact made it unlikely
that vedolizumab would result in general immunosup-
pression or an increased PML risk [19, 20].
Although cases of PML have been initially detected
radiographically, diagnosis is most often based on clinical
suspicion in at-risk patients who exhibit symptoms (typi-
cally a change in neurological symptoms or function).
Thereafter, a confirmatory evaluation typically includes a
combination of the following: brain magnetic resonance
imaging (MRI) revealing characteristic white matter
lesions, and either lumbar puncture with detection of JC
viral DNA in cerebrospinal fluid (CSF) by polymerase
chain reaction (PCR) or biopsy evidence of JC virus in
brain tissue [21]. For these reasons, the RAMP focused on
patient and study site staff education about the presenting
signs and symptoms of PML through standardised teaching
materials. The programme also utilised screening ques-
tionnaires to monitor PML risk throughout a patient’s time
on-study, and a stepwise management algorithm for
potential cases. When cases of persistent, new, unexplained
neurological symptoms arose, they were adjudicated by a
panel of experts with extensive expertise in diagnosing
PML (all co-authors of this report).
In this study, we present the cumulative experience
involving approximately 3000 patients with UC or CD over
the course of 7 years of vedolizumab clinical development.
From these data, we propose that the RAMP constitutes a
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staged, pragmatic risk management tool for use in clini-
cal trials of investigational agents for which the possibility
of drug-associated PML represents an important
consideration.
2 Methods
2.1 Studies and Patients
The RAMP was implemented in six vedolizumab phase II
and III clinical trials in patients with UC or CD (Table 1).
These studies were conducted at approximately 300 study
sites in nearly 40 countries in North America, Europe,
Asia, Africa, and Australia.
Prior to study enrolment, informed consent regarding a
potential risk of PML associated with administration of the
study drug was obtained. The text of the informed consent
form can be found in Electronic Supplementary Material 2.
Protocol eligibility criteria, including PML checklists
(described below), were utilised to screen for patients who
were either deemed to be at increased risk of PML based on
a set of predefined criteria, or had other neurological
diagnoses that would render an evaluation of PML more
difficult, e.g. multiple sclerosis.
2.2 Subject and Staff Education
Patients were provided with a brochure written in lay
language describing the risks of PML. as well as the
presenting neurological symptoms for which to remain
vigilant (Electronic Supplementary Material 3). Patients
were also given a wallet card, which concisely summarised
the information in the brochure, for portability and easy
reference (Electronic Supplementary Material 4).
Study staff (including investigators, nurses, and clinical
study coordinators) were trained on the pathophysiology
and natural history of PML, including signs and symptoms
of disease. They were also educated on the importance of
the cessation of administration of vedolizumab and the
expedited evaluation of suspected PML cases when sus-
picion of PML was high. A brochure suitable for medical
personnel containing detailed technical language was pro-
vided to each member of the study staff (Electronic Sup-
plementary Material 5). The principal investigators were
generally gastroenterologists, rather than neurologists. For
that reason, investigator training included a video demon-
stration of how to perform a targeted neurological exami-
nation to evaluate common clinical presentations of PML
(e.g. aphasia, limb weakness, etc.). The video was provided
to all investigators in DVD format for quick reference.
We required a local neurologist to be included as a sub-
investigator at each clinical study site; however, PML is an
uncommon disease and even experienced neurologists lack
first-hand familiarity with the acute clinical presentation.
For this reason, we trained the local neurologist on the
important clinical features that might indicate a PML
diagnosis, and provided the study protocol in advance of
initiating the trial.
Table 1 RAMP programme implementation: multiple-dose studies in patients with IBDa
Study Phase Design Patients
C13002
[29]
II Double-blind, randomised,
placebo-controlled
Had active UC and were receiving stable doses of oral 5-aminosalicylates, corticosteroids,
and/or purine antimetabolites or methotrexate (n = 46)
C13004
[30]
II Open-label, long-term Had active UC and were treatment-naive, had participated in study C13002, or had CD and
were treatment-naive (N = 72;b 53 UC patients and 19 CD patients)
C13006
[31]
III Double-blind, randomised,
placebo-controlled
Had moderately to severely active UC with documented failure or intolerance to one or
more corticosteroids, immunosuppressives (i.e. azathioprine/6-mercaptopurine), or TNF
antagonists (n = 895)
C13007
[32]
III Double-blind, randomised,
placebo-controlled
Had moderately to severely active CD and were unresponsive or intolerant to one or more
of the following: corticosteroids, immunosuppressives (i.e. azathioprine/6-
mercaptopurine/methotrexate), or TNF antagonists (n = 1115)
C13011
[33]
III Double-blind, randomised,
placebo-controlled
Had moderately to severely active CD, and most had previous TNF-antagonist failure
(n = 416)
C13008
[34, 35]
III Open-label, long-term Had moderately to severely active UC or CD, and either participated in studies C13004,
C13006, C13007 or C13011 or were treatment-naive (n = 2244)
CD Crohn’s disease, TNF tumour necrosis factor, UC ulcerative colitis, PML progressive multifocal leukoencephalopathy, IBD inflammatory
bowel disease, RAMP Risk Assessment and Minimisation for PML
aPML checklist findings were not summarised for the five studies in healthy volunteers because of limited drug exposure (i.e. one dose) and a
lack of concomitant risk factors
bPatients from the C13002 study could rollover into this study. Of the 53 UC patients, 38 rolled over and 19 were treatment-naive; all 19 CD
patients were treatment-naive
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At investigator meetings and mid-study refresher web-
based conferences, study staff were also trained on the
PML checklists (described below) and the PML case
evaluation algorithm, which were to be used at each patient
visit to systematically evaluate and triage new, unexplained
neurological findings.
2.3 Progressive Multifocal Leukoencephalopathy
(PML) Checklists, PML Case Evaluation
Algorithm, and Serum JC Virus Assay
An Independent Adjudication Committee (IAC) was formed
with the purpose of providing an independent, unbiased
opinion regarding the likelihood of PML in a subject who
developed new neurological symptoms or signs, or who
otherwise met criteria that indicated a clinical suspicion of
PML. The subjective PML checklist and objective PML
checklist can be found in Electronic SupplementaryMaterial
6, and a description of how IAC experts were identified and
the charter describing roles and responsibilities, process
flow, and scoring systems for case evaluation can be found in
Electronic Supplementary Material 2.
The IAC, together with the sponsor, created a PML case
evaluation algorithm for sequential screening and diag-
nostic evaluation (Fig. 1). This algorithm follows a step-
wise series of measures to diagnose PML, including brain
MRI and lumbar puncture. A detailed description of the
algorithm and its individual steps can be found in Elec-
tronic Supplementary Material 2.
Following publication of an American Association of
Neurology (AAN) consensus position on diagnostic criteria
for PML in 2013, these criteria were adopted into the
RAMP to define PML cases [21].
Blood-based assessment of JC viral DNA by PCR was
initially performed as an exploratory biomarker for PML risk
based on the most current state of understanding in 2007.
Sera were collected longitudinally and stored, then assessed
retrospectively in batches. However, over the course of
vedolizumab clinical development, this potential biomarker
was found to lack predictive value [22]; hence, following
discussion with key regulatory authorities, that assessment
was discontinued. The JCV serologic assay, developed
subsequently and ultimately proven to have predictive value,
was not available during our investigation [23].
2.4 Adjudication of Potential Cases
IAC neuroradiologists were asked to utilise a 0–5 Likert
scale (5 being highest) to assign the probability of PML
based on the imaging findings (see Electronic Supple-
mentary Material 1: Table S1). In the event of a discrep-
ancy, the neuroradiologists were to confer and assign a
single score.
Within 48 h of receiving the data, IAC members were
expected to record their reviews on evaluation worksheets
that they forwarded to the IAC chairperson, who then
collated the judgements in these reviews and provided a
final assessment of the case to the sponsor, documenting
key findings and assessing the likelihood of PML based on
the qualitative scale below early in the programme, and the
AAN consensus criteria later in the programme.
• Not PML.
• Possible PML. More information is needed to exclude
or confirm diagnosis.
• Probable PML. Very strong clinical suspicion in the
absence of CSF PCR results and brain histopathology
results.
• Definite PML. Positive CSF PCR analysis for JC virus
or confirmed brain histopathology.
If the assessment could not be completed based on
incomplete data, additional data were requested from the
study site. Once all IAC members had performed their
analysis, the IAC Chairperson provided a signed memo-
randum to the sponsor with a brief synopsis of key findings
and the consensus assessment, either making a determi-
nation of PML or not PML, or requesting additional
information. The IAC recommendations were not consid-
ered binding given the fact that clinical care was intended
to occur according to local standards.
2.5 Post-Study Telephone Follow-Up
Once patients concluded study participation, they were
contacted at 6-month intervals, for a period of 2 years, by a
telephone call centre, a Clinical Research Organisa-
tion (CRO) representative or the enrolling site, to be asked
focused questions about their health, including occurrence of
surgery, hospitalisation, serious infection, cancer and clini-
cal features suggestive of PML (see Electronic Supplemen-
tary Material 7). A minimum of four attempts at telephone
calls weremade to reach each patient at each time point, even
if attempts at prior time points had been unsuccessful. The
sponsor received email alerts for any positive responses.
3 Results
3.1 Checklist Findings
The vedolizumab phase III clinical development pro-
gramme spanned 7 years and included 2884 patients (1114
with UC; 1770 with CD). The mean duration of exposure
was approximately 450 days per patient (range 0–1865).
Exposure duration of[ 2 years and prior and current
immunosuppressive use are well-recognised risk factors for
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PML with natalizumab. A total of 835 vedolizumab
patients had over 2 years of exposure, approximately 80%
had prior immunosuppressive use (thiopurines,
methotrexate), and 30% had current use.
As of March 2013, 2913 patients (UC: 1142; CD: 1771)
(Table 2) completed 57,986 subjective checklists (UC:
24,919; CD: 33,067). Positive subjective findings led to
completion of 167 and 342 objective checklists in 95 UC
patients and 189 CD patients, respectively. Very few
patients (\ 1.0%) indicated a positive response at baseline
for the subjective checklist questions; those who did were
excluded from enrolling. All neurologic signs and
Fig. 1 RAMP programme case evaluation algorithm. CSF cerebrospinal fluid, IAC Independent Adjudication Committee, JCV JC virus, MRI
magnetic resonance imaging, PCR polymerase chain reaction
Table 2 Summary of PML
checklist results
UC CD Total
Patients with a subjective PML checklist administered [n (%)]a n = 1142 n = 1771 n = 2913
Positive subjective findings 95 (8) 189 (11) 284 (10)
Objective PML checklist administered 95 (8) 189 (11) 284 (10)
Abnormal objective findings 17 (1) 45 (3) 62 (2)
Subjective checklists administered [n (%)] n = 24,919 n = 33,067 n = 57,986
Positive subjective findings 167 (\ 1) 342 (1) 509 (\ 1)
Objective PML checklist administered 165 (\ 1) 341 (1) 506 (\ 1)
Abnormal objective findings 18 (\ 1) 51 (\ 1) 69 (\ 1)
CD Crohn’s disease, UC ulcerative colitis, PML progressive multifocal leukoencephalopathy
aProportions are based on the number of patients who completed one or more subjective checklists
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symptoms that led to positive subjective findings or
abnormal objective findings are shown in Fig. 2. Positive
responses were most commonly sensory in origin (e.g.
paraesthesias, numbness, etc.), followed by visual findings
and limb weakness less commonly reported.
3.2 Algorithm Utilisation
The IAC evaluated suspected cases involving 83 patients
(UC: 24; CD: 59) (Table 3). Adjudication was achieved
within 7 days for approximately two-thirds of these cases,
which included 62 patients with abnormal objective
checklist results (UC: 17; CD: 45) (Table 2) and 21
additional patients (UC: 7; CD: 14) who were referred with
complaints as a precautionary measure, but without
objective findings. Although further diagnostic evaluation
in the latter group was not mandated by the RAMP, these
patients were included here for the sake of comprehensive
patient monitoring in light of the serious nature of PML.
From the 83 patients, the IAC recommended brain MRIs
in 56 patients (Table 3). The MRI results were inconsistent
with PML, with a limited number of patients scoring 1–2
on the radiographic scale in the charter, and no individual
patient having a score of 3 or higher. Diagnostic evaluation
in 5 patients included lumbar puncture with PCR analysis
of CSF for JC virus (UC: 2; CD: 3), all of which were
Fig. 2 Positive subjective
checklist findings: signs and
symptoms1. 1Subjective
checklist symptoms:
gait/coordination (e.g. bumping
into objects, difficulty writing);
confusion (e.g. problems with
memory/thinking); vision/
ocular motility (e.g. difficulty
reading); sensation (e.g. loss,
numbness); speaking (e.g.
dysarthria, aphasia);
comprehension (e.g. inability to
follow serial commands);
weakness/spasticity (e.g.
pronator drift, lack of muscle
strength)
Table 3 Summary of RAMP
algorithm results
UC CD Total
Patients [n (%)]a n = 1114 n = 1770 n = 2884
Referred to a neurologist 24 (2) 58 (3) 82 (3)
MRI performed 15 (1) 41 (2) 56 (2)
IAC involved 24 (2) 59 (3) 83 (3)
Lumbar puncture 2 (\ 1) 3 (\ 1) 5 (\ 1)
CSF analysed by PCR for JC viral DNA 2 (\ 1) 3 (\ 1) 5 (\ 1)
JC viral DNA detected by PCR in CSF 0 0 0
Diagnosed with PML by the IAC 0 0 0
CSF cerebrospinal fluid, IAC Independent Adjudication Committee, MRI magnetic resonance imaging,
PCR polymerase chain reaction, PML progressive multifocal leukoencephalopathy, UC ulcerative colitis,
CD Crohn’s disease, RAMP Risk Assessment and Minimisation for PML
aProportions are based on the number of patients who completed one or more subjective checklists and who
had complete information in the RAMP algorithm section of the case report form
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negative. Given the fact that lumbar puncture is an invasive
procedure and a common penultimate step in confirming
PML, case history narratives for those five patients are
provided in Electronic Supplementary Material 1:
Table S2. No PML cases were identified by the IAC
through 14 March 2013. Vedolizumab was approved by the
US FDA and the European Medicines Agency in May
2014, and received over 50 approvals in countries around
the world thereafter.
3.3 Post-Study Follow-Up (Up to 2 Years Per
Patient at 6-Month Intervals)
As of March 2013, 1382 of 1794 (77%) patients provided
responses to at least one post-study telephone follow-up
survey. For the 24-months post-study time point, data from
562 patients (67% of eligible patients) were available.
There were no reports of symptoms or signs referable to a
PML diagnosis during this period.
4 Discussion
Because no validated method exists to screen for PML, the
RAMP was devised as a clinical trial tool to address this
potential risk. It consisted of a comprehensive evaluation,
which included (1) exclusion of patients at higher risk of
PML; (2) exclusion of patients in whom PML diagnosis
might be more difficult to ascertain; (3) monitoring all
patients for their risk of PML throughout their duration of
the study using screening questionnaires; (4) objective
testing; (5) a sequential case evaluation algorithm; and (6)
post-study telephone follow-up.
Although sequential MRI scans are helpful in the diag-
nosis of PML when patients are still asymptomatic, early
symptoms are the most practical means for early detection
of the onset of PML. Because early diagnosis has been
demonstrated to improve the likelihood of survival with
less permanent neurological injury, we considered the use
of early and frequent screening via questionnaires an
important objective [24].
Neurological symptoms are common and occur more
frequently in the IBD population than in the general pop-
ulation [25], as do white matter lesions on MR imaging
[26]. This fact could theoretically confound the diagnosis
of PML in this population. Moreover, IBD patients are
usually cared for by gastroenterologists rather than neu-
rologists, a fact that could make timely diagnosis of drug-
associated PML more challenging. As a result, it was not
evident from the outset how to create a system that is both
sensitive enough to detect PML cases early in their course,
while maintaining specificity in the face of many transient
neurological symptoms that are inconsistent with PML. It
was also not known if non-neurologists would respond well
to the trainings and gain comfort with the subjective and
objective facets of testing for a neurological disease. The
types of symptoms and signs indicative of PML that were
most likely to be detected by the questionnaires are not
routinely evaluated by the cohort of investigators involved
in the vedolizumab trials. Finally, the RAMP as a previ-
ously unvalidated algorithm, necessitated a high degree of
compliance with risk minimisation procedures and associ-
ated timelines to assess its potential usefulness. It was not
known at the outset what level of compliance might be
achievable.
The overall experience with implementation of the
RAMP across the clinical trial programme for vedolizumab
revealed a low percentage of positive subjective checklists.
Because PML is typified by new progressive neurological
dysfunction, it seemed unlikely for symptoms consistent
with PML to be missed based on the questions posed.
Furthermore, gastroenterologists were able to successfully
administer objective testing as qualitatively assessed by
trainings, queries, source data verification, interaction with
investigators, and compliance metrics, resulting in minimal
demand for consultation with study neurologists. MRIs
were performed in few patients overall, and even fewer
outside of algorithm requirements.
A very small number of patients (5, approximately 0.2%
of the study population) underwent lumbar puncture, the
most invasive procedure necessitated by the RAMP for
establishing PML diagnosis. As for MRIs, a lumbar
puncture for CSF JCV analysis was not indicated by
algorithm in all instances; three of these were performed
electively by the local caring physician, and, in two of
those instances, CSF had been collected for other standard-
of-care assessments. JC viral DNA was not detected in any
CSF sample, and these negative findings (and the IAC’s
judgements) were confirmed by the fact that PML did not
develop in any patients during the follow-up period.
One could speculate that baseline or longitudinal MRIs
might have avoided the need for lumbar puncture in at least
a few subjects; however, experience from the RAMP
shows that the on-study MRIs were generally interpretable,
even in the absence of a baseline examination. Moreover,
performing thousands of potentially unhelpful MRIs to
possibly prevent a very limited number of lumbar punc-
tures argues against their clinical utility. For vedolizumab,
with the evidence for gut selective biology and the absence
of any proven PML events, MRIs would have represented
an extremely low yield approach toward risk minimisation.
For a drug with a very different pharmacologic or benefit-
to-risk profile, the relative merits of MRI monitoring could
be considered as part of a tailored approach.
The data derived from this risk minimisation plan allow
us to make useful inferences about the risk of PML in the
Risk Assessment and Minimisation of PML in Vedolizumab Clinical Trials 813
vedolizumab-exposed population (the actual PML risk
estimates from this dataset have been published elsewhere)
[27]. The tools created and utilised are not vedolizumab or
integrin antagonist specific. This fact lends strength and
generalisability to other clinical development programmes
where PML represents an actual or theoretical considera-
tion. The checklists are simple and intuitive and do not
require PML experts or neurologists to administer. The
stepwise sequential evaluation mirrors clinical care and
reserves more invasive testing for instances of higher
clinical suspicion. Multiple checks and balances help
ensure that new neurological symptoms are carefully fol-
lowed and their evolution assessed in a timely manner.
Given the rapidly progressive nature of clinical PML, it
was important that the RAMP worked efficiently because
delays in PML diagnosis could result in serious disability
or death. In this global clinical trial programme with
patients on five continents, adjudication was achieved
within 7 days for approximately two-thirds of the cases;
others required more time, often due to operational con-
straints (e.g. translation of medical documents, technical
challenges with obtaining MRI scans, etc.). Although this
was simply an assumption when the RAMP was devised,
recent data suggest that early diagnosis of PML results in
better outcomes [28]. Thus, the potential for investigators
to receive expert feedback on PML likelihood and appro-
priate intervention measures within days is highly desir-
able. Patient and study staff education, training, and real-
time support played an important role in clarifying the
likelihood of development of this potentially devastating
yet difficult-to-diagnose disease process, allowing the
clinical development programme for vedolizumab to
progress.
A limitation of the RAMP is the difficulty in ascer-
taining the predictive value of measures put in place in the
absence of PML events. One option would be to utilise the
RAMP or appropriate adaptation in a context with a better
understood background rate of PML. Another limitation is
the fact that the RAMP was performed uniquely in the
clinical trial setting. The overwhelming amount of
immunosuppressive use occurs in a real-world setting
without case report forms, checklists or other systematic
data collection methods. Some elements of the RAMP, e.g.
elements of the informed consent language or educational
materials, could potentially be adapted to serve real-world
needs; however, pragmatic considerations could limit the
utility of certain other RAMP components. While it is
possible that PML cases could have gone undetected in
spite of methods described herein, the authors have con-
cluded that the extent of awareness and data collection via
the RAMP, coupled with the progressive nature of PML,
makes this possibility unlikely. Of note, since the approval
of vedolizumab in many parts of the world in 2014, no
cases of PML have been spontaneously reported, or
otherwise identified, as of the submission of this manu-
script [29].
5 Conclusions
The RAMP programme reported here demonstrates prac-
tical and effective screening and surveillance measures that
can be used in clinical trials to manage potential PML risks
of investigational or approved treatments. Implementation
of the RAMP in a large global clinical trial programme was
comprehensive and achievable, with high levels of com-
pliance. No cases of PML were detected with vedolizumab
in a patient population with at least some risk factors,
suggesting a low likelihood of any relationship between
vedolizumab mechanism of action and PML risk. Many
elements of this plan could be utilised in other clinical trial
programmes. Certain RAMP elements could be adapted for
use in a real-world setting, however other measures are
unlikely to be feasible or warranted. The RAMP cannot be
validated in the absence of PML events; thus, future work
should include assessing this programme in conjunction
with drugs with proven PML risk. Additional work might
include assessment of the RAMP by patients and health-
care professionals.
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